Gerald J. Gleich,
MD
No Rating Available?
1 4.7
out of
5
Patient Rating
In order to provide our patients and visitors with the most accurate and useful information, we only post physician satisfaction data when a physician has received a minimum of 30 returned surveys. For this provider, we have not yet received the
minimum.
Languages Spoken: English
Gerald Gleich, MD is an allergist and immunologist with a practice focused on the treatment of eosinophil-associated diseases. These include asthma, esophagitis and hypereosinophilic syndromes, as well as more common allergic diseases such as allergic conjunctivitis, allergic rhinitis (hay fever), chronic rhinosinusitis, atopic dermatitis (eczema), and urticaria (hives). He is board certified in Internal Medicine, and Allergy and Immunology. His research interests are in the study of eosinophils and allergic inflammatory reactions.
Clinical Locations
801-581-2955
Board Certification and Academic Information
| Academic Departments | Dermatology
-
Research Professor Pediatrics - Adjunct Professor |
| Academic Divisions | Pediatric Allergy and Immunology |
| Board Certification | American Board of Allergy & Immunology American Board of Internal Medicine (Internal Medicine) American Board of Internal Medicine (Sub: Allergy & Immun) |
Patient Rating
The Patient Rating score is an average of all responses to care provider related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Likelihood of recommending care provider
4.6/ 5
Care provider's explanation of condition/problem
4.7/ 5
Care provider's effort to include me in decisions
4.8/ 5
Wait time at clinic
3.9/ 5
Care provider's concern for questions & worries
4.7/ 5
Patient Comments
Patient comments are gathered from our Press Ganey Patient Satisfaction Survery and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.
UofU Patient
May 01, 2020
UNIVERSITY OF UTAH MIDVALLEY HEALTH CENTER
The doctor was 55 minutes late to my appointment
Gerald Gleich, MD is an allergist and immunologist with a practice focused on the treatment of eosinophil-associated diseases. These include asthma, esophagitis and hypereosinophilic syndromes, as well as more common allergic diseases such as allergic conjunctivitis, allergic rhinitis (hay fever), chronic rhinosinusitis, atopic dermatitis (eczema), and urticaria (hives). He is board certified in Internal Medicine, and Allergy and Immunology. His research interests are in the study of eosinophils and allergic inflammatory reactions.
Academic Locations
School of Medicine
801-581-6465
Board Certification and Academic Information
| Academic Departments | Dermatology
-
Research Professor Pediatrics - Adjunct Professor |
| Academic Divisions | Pediatric Allergy and Immunology |
| Board Certification | American Board of Allergy & Immunology American Board of Internal Medicine (Internal Medicine) American Board of Internal Medicine (Sub: Allergy & Immun) |
Research Interests
- Functions of Eosinophils
- Structure and Function of Eosinophil Granule Proteins
- Pathophysiology of Allergic Inflammatory Reactions
- Spanish Toxic Oil Syndrome and the Eosinophilia Myalgia Syndrome
- Role of the Eosinophil Granule Major Basic Protein in Human Pregnancy
Education History
| Fellowship | Strong Memorial Hospital Allergy & Immunology Fellow |
| Residency | Jackson Memorial Hospital Internal Medicine Resident |
| Internship | Philadelphia General Hospital Medicine Intern |
| Professional Medical | University of Michigan Medicine M.D. |
| Undergraduate | University of Michigan Premedical Sciences B.A. |
Selected Publications - Journal Articles
Journal Article
- Squillace DL, Checkel JL, Tefferi A, Kita H, Gleich GJ (2021). Development and application of novel immunoassays for eosinophil granule major basic proteins to evaluate eosinophilia and myeloproliferative disorders. J Immunol Methods, 493, 113015.
- Muraki M, Kita H, Gleich GJ (2020). Dexamethasone and lidocaine suppress eosinophilopoiesis from umbilical cord blood cells. Clinical and Molecular Allergy, 18(1), 24.
- Roufosse F, Kahn JE, Rothenberg ME, Wardlaw AJ, Klion AD, Kirby SY, Gilson MJ, Bentley JH, Bradford ES, Yancey SW, Steinfeld J, Gleich GJ, HES Mepolizumab study group (2020). Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial. J Allergy Clin Immunol, 146(6), 1397-1405.
- Peterson K, Lin E, Saffari H, Qeadan F, Pyne A, Firszt R, Robson J, Gleich G (2020). Food-specific antibodies in oesophageal secretions: association with trigger foods in eosinophilic oesophagitis. Aliment Pharmacol Ther, 52(6), 997-1007.
- Dong ZM, Lin E, Wechsler ME, Weller PF, Klion AD, Bochner BS, Delker DA, Hazel MW, Fairfax K, Khoury P, Akuthota P, Merkel PA, Dyer AM, Langford C, Specks U, Gleich GJ, Chinchilli VM, Raby B, Yandell M, Clayton F (2020). Pulmonary Eosinophilic Granulomatosis with Polyangiitis Has IgG4 Plasma Cells and Immunoregulatory Features. Am J Pathol, 190(7), 1438-1448.
- Saffari H, Peterson KA, Leiferman KM, Stabin MG, Krstyen JJ, Clayton FC, Pease LF 3rd, Yap JT, Hoffman JM, Gleich GJ (2019). Oral Administration of 99mTechnetium-Labeled Heparin in Eosinophilic Esophagitis. Mayo Clin Proc, 95(3), 449-458.
- Peterson KA, Gleich GJ, Limaye NS, Crispin H, Robson J, Fang J, Saffari H, Clayton F, Leiferman KM (2019). Eosinophil granule major basic protein 1 deposition in eosinophilic esophagitis correlates with symptoms independent of eosinophil counts. Dis Esophagus, 32(11).
- Patel AB, Franzini A, Leroy E, Kim SJ, Pomicter AD, Genet L, Xiao M, Yan D, Ahmann JM, Agarwal AM, Clair P, Addada J, Lambert J, Salmon M, Gleich GJ, Cross NCP, Constantinescu SN, OHare T, Prchal JT, Deininger MW (2019). JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera. Blood, 134(26), 2388-2398.
- Lee LY, Gu Q, Lin AH, Khosravi M, Gleich G (2019). Airway hypersensitivity induced by eosinophil granule-derived cationic proteins. Pulm Pharmacol Ther, 57, 101804.
- Lin AH, Athukorala A, Gleich GJ, Lee LY (2019). Cough responses to inhaled irritants are enhanced by eosinophil major basic protein in awake mice. Am J Physiol Regul Integr Comp Physiol, 317(1), R93-R97.
- Steinfeld J, Bradford ES, Brown J, Mallett S, Yancey SW, Akuthota P, Cid MC, Gleich GJ, Jayne D, Khoury P, Langford CA, Merkel PA, Moosig F, Specks U, Weller PF, Wechsler ME (2018). Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol, 143(6), 2170-2177.
- Saffari H, Peterson KA, Fang JC, Teman C, Gleich GJ, Pease LF 3rd (2012). Patchy eosinophil distributions in an esophagectomy specimen from a patient with eosinophilic esophagitis: Implications for endoscopic biopsy. J Allergy Clin Immunol, 130(3), 798-800.
- Valent P, Klion AD, Horny HP, Roufosse F, Gotlib J, Weller PF, Hellmann A, Metzgeroth G, Leiferman KM, Arock M, Butterfield JH, Sperr WR, Sotlar K, Vandenberghe P, Haferlach T, Simon HU, Reiter A, Gleich GJ (2012). Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol, 130(3), 607-612.e9.
- Plager DA, Davis MD, Andrews AG, Coenen MJ, George TJ, Gleich GJ, Leiferman KM (2009). Eosinophil ribonucleases and their cutaneous lesion-forming activity. J Immunol, 183(6), 4013-20.
- Gleich GJ, Leiferman KM (2009). The hypereosinophilic syndromes: current concepts and treatments. Br J Haematol, 145(3), 271-85.
- Rothenberg ME, Klion AD, Roufosse FE, Kahn JE, Weller PF, Simon HU, Schwartz LB, Rosenwasser LJ, Ring J, Griffin EF, Haig AE, Frewer PI, Parkin JM, Gleich GJ (2008). Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med, 358(12), 1215-28.
- Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH (2002). Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet, 359(9317), 1577-8.
- Gleich GJ (2000). Mechanisms of eosinophil-associated inflammation. J Allergy Clin Immunol, 105(4), 651-63.
- Gleich GJ, Schroeter AL, Marcoux JP, Sachs MI, OConnell EJ, Kohler PF (1984). Episodic angioedema associated with eosinophilia. N Engl J Med, 310(25), 1621-6.
Review
- Gleich GJ (1990). The eosinophil and bronchial asthma: current understanding. [Review]. J Allergy Clin Immunol, 85(2), 422-36.
- Frigas E, Gleich GJ (1986). The eosinophil and the pathophysiology of asthma. [Review]. J Allergy Clin Immunol, 77(4), 527-37.
Letter
- Zussman J, Gleich GJ (2018). Allergic rhinitis and asthma induced by boxelder bug sensitization. [Letter to the editor]. J Allergy Clin Immunol Pract, 7(4), 1365-1366.
- Ortega HG, Meyer E, Brusselle G, Asano K, Prazma CM, Albers FC, Mallett SA, Yancey SW, Gleich GJ (2019). Update on immunogenicity in severe asthma: Experience with mepolizumab. [Letter to the editor]. J Allergy Clin Immunol Pract, 7(7), 2469-2475.e1.
- Rosenberg HF, Fryer AD, Munitz A, Bochner BS, Jacoby DB, Levi-Schaffer F, Gleich GJ, Furuta GT, Rothenberg ME, Lacy P, Fulkerson PC, Hogan SP, Ackerman SJ, Foster PS (2017). In Memory and Celebration: Dr. James J. Lee. [Letter to the editor]. Clin Exp Allergy, 47(7), 980-981.
Patent
- Gleich GJ, Bankers-Fulbright JL, O'Grady S (2002). Topical Anesthetics for Treating Cancer. U.S. Patent No. 6391888. Washington, D.C.:U.S. Patent and Trademark Office.
- Gleich GJ, Ohnishi T, Hunt LW (2000). Use of Topical Anesthetics for the Manufacture of a Medicament for the Treatment of Bronchial Asthma. U.S. Patent No. 0682514. Washington, D.C.:U.S. Patent and Trademark Office.
- Gleich GJ, Hunt LW (2000). Methods of Treating Neutrophil-Related Diseases with Topical Anesthetics. U.S. Patent No. 60214031. Washington, D.C.:U.S. Patent and Trademark Office.
- Gleich GJ, Bankers-Fulbright JL (2000). Use of Agents to Treat Eosinophil-Associated Pathologies. U.S. Patent No. 6071910. Washington, D.C.:U.S. Patent and Trademark Office.
- Gleich GJ, Levy AM, Sandborn WJ, Tremaine WJ, Steiner BL, Phillips SF (1999). Eosinophil Granule Proteins as Indicators of Inflammatory Bowel Disorders. U.S. Patent No. 5928883. Washington, D.C.:U.S. Patent and Trademark Office.
- Gleich GJ (1998). Treatment of Eosinophil-Associated Pathologies by Administration of Topical Anesthetics and Glucocorticoids. U.S. Patent No. 5837713. Washington, D.C.:U.S. Patent and Trademark Office.
- Scott RW (1998). Basophil Granules Proteins. U.S. Patent No. 8977812. Washington, D.C.:U.S. Patent and Trademark Office.
- Scott RW, Gleich GJ, Wilde CG (1998). Basophil Granule Proteins. U.S. Patent No. 5747283. Washington, D.C.:U.S. Patent and Trademark Office.
- Gleich GJ (1997). Method for the Treatment of Bronchial Asthma by Parenteral Administration of Anionic Polymers. U.S. Patent No. 5681555. Washington, D.C.:U.S. Patent and Trademark Office.
- Gleich GJ, Ohnishi T, Hunt LW (1997). Method for the Treatment of Eosinophil-Associated Diseases by Administration of Topical Anesthetics. U.S. Patent No. 5631267. Washington, D.C.:U.S. Patent and Trademark Office.
- Gleich GJ, Ohnishi T, Hunt LW (1996). Method for the Treatment of Bronchial Asthma by Administration of Topical Anesthetics. U.S. Patent No. 5510339. Washington, D.C.:U.S. Patent and Trademark Office.
- Gleich GJ (1996). Method for the Treatment of Eosinophil-Associated Conditions with Anionic Polymers. U.S. Patent No. 5498410. Washington, D.C.:U.S. Patent and Trademark Office.
- Scott RW, Gleich GJ, Wilde CG (1995). Basophil Granule Proteins. U.S. Patent No. 5476839. Washington, D.C.:U.S. Patent and Trademark Office.
- Scott RW, Gleich GJ, Wilde CG (1995). Basophil Granule Proteins. U.S. Patent No. 5470825. Washington, D.C.:U.S. Patent and Trademark Office.
- Gleich GJ (1993). Method for the Treatment of Hypersensitivity Diseases by Administration of Anionic Polymers. U.S. Patent No. 5250293. Washington, D.C.:U.S. Patent and Trademark Office.
- Gleich GJ, Wasmoen TL (1987). Method for the Determination of the Imminence of Labor. U.S. Patent No. 4710475. Washington, D.C.:U.S. Patent and Trademark Office.